Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Exposure-response analysis after subcutaneous administration of RBP-7000, a once-a-month long-acting Atrigel formulation of risperidone.

Ivaturi V, Gopalakrishnan M, Gobburu JVS, Zhang W, Liu Y, Heidbreder C, Laffont CM.

Br J Clin Pharmacol. 2017 Jul;83(7):1476-1498. doi: 10.1111/bcp.13246. Epub 2017 Mar 31.

PMID:
28133766
2.

A population approach to characterise amisulpride pharmacokinetics in older people and Alzheimer's disease.

Reeves S, Bertrand J, D'Antonio F, McLachlan E, Nair A, Brownings S, Greaves S, Smith A, Taylor D, Howard R.

Psychopharmacology (Berl). 2016 Sep;233(18):3371-81. doi: 10.1007/s00213-016-4379-6. Epub 2016 Aug 1.

3.

Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable With Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial.

Nakajima S, Uchida H, Bies RR, Caravaggio F, Suzuki T, Plitman E, Mar W, Gerretsen P, Pollock BG, Mulsant BH, Mamo DC, Graff-Guerrero A.

Schizophr Bull. 2016 Jan;42(1):212-9. doi: 10.1093/schbul/sbv106. Epub 2015 Jul 28.

4.
5.

Optimal sampling of antipsychotic medicines: a pharmacometric approach for clinical practice.

Perera V, Bies RR, Mo G, Dolton MJ, Carr VJ, McLachlan AJ, Day RO, Polasek TM, Forrest A.

Br J Clin Pharmacol. 2014 Oct;78(4):800-14. doi: 10.1111/bcp.12410.

6.

Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data.

Yoshida K, Bies RR, Suzuki T, Remington G, Pollock BG, Mizuno Y, Mimura M, Uchida H.

Schizophr Res. 2014 Mar;153(1-3):184-8. doi: 10.1016/j.schres.2014.01.017. Epub 2014 Feb 1.

7.
8.

Population pharmacokinetics of clozapine and its primary metabolite norclozapine in Chinese patients with schizophrenia.

Li LJ, Shang DW, Li WB, Guo W, Wang XP, Ren YP, Li AN, Fu PX, Ji SM, Lu W, Wang CY.

Acta Pharmacol Sin. 2012 Nov;33(11):1409-16. doi: 10.1038/aps.2012.71. Epub 2012 Jul 23.

9.

Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model building.

Sherer EA, Sale ME, Pollock BG, Belani CP, Egorin MJ, Ivy PS, Lieberman JA, Manuck SB, Marder SR, Muldoon MF, Scher HI, Solit DB, Bies RR.

J Pharmacokinet Pharmacodyn. 2012 Aug;39(4):393-414. doi: 10.1007/s10928-012-9258-0. Epub 2012 Jul 6.

10.

Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data.

Sakurai H, Bies RR, Stroup ST, Keefe RS, Rajji TK, Suzuki T, Mamo DC, Pollock BG, Watanabe K, Mimura M, Uchida H.

Schizophr Bull. 2013 May;39(3):564-74. doi: 10.1093/schbul/sbr189. Epub 2012 Jan 30.

11.

Pharmacogenetics of antipsychotic treatment response and side effects.

Mackenzie B, Souza R, Likhodi O, Tiwari A, Zai C, Sturgess J, Müller D.

Therapy. 2010 Mar;7(2):191-198.

12.

Development of a complex parent-metabolite joint population pharmacokinetic model.

Bertrand J, Laffont CM, Mentré F, Chenel M, Comets E.

AAPS J. 2011 Sep;13(3):390-404. doi: 10.1208/s12248-011-9282-9. Epub 2011 May 27.

13.

Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smoking.

Jin Y, Pollock BG, Coley K, Miller D, Marder SR, Florian J, Schneider L, Lieberman J, Kirshner M, Bies RR.

J Clin Pharmacol. 2010 Jan;50(1):73-80. doi: 10.1177/0091270009343694. Epub 2009 Oct 20.

Supplemental Content

Support Center